Acquisitions - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2019	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill		$ 140,627,000		$ 140,627,000		$ 140,627,000
Estimated fair value of contingent consideration, long-term liabilities		111,856,000		111,856,000		109,606,000
Change in the estimated fair value of contingent consideration				2,250,000	$ (47,223,000)
Cobalt Biomedicine, Inc | Acquisition Agreement
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	100.00%
Business acquisition, impairment of intangible assets or goodwill	$ 0
Goodwill	140,600,000
Maximum contingent consideration upon achievement of certain pre-specified development milestones	$ 500,000,000.0
Maximum term for success payment	20 years
Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development Expense
Business Acquisition [Line Items]
Estimated fair value of contingent consideration		111,900,000		111,900,000		109,600,000
Change in estimated fair value of success payment		(4,900,000)	$ (22,000,000)	2,300,000	(8,300,000)
Change in the estimated fair value of contingent consideration		200,000	$ (58,600,000)	2,300,000	$ (47,200,000)
Cobalt Biomedicine, Inc | Acquisition Agreement | Long-term Liabilities | Research and Development Expense
Business Acquisition [Line Items]
Estimated fair value of success payment liability		$ 13,500,000		$ 13,500,000		$ 11,200,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Minimum
Business Acquisition [Line Items]
Threshold market capitalization	$ 8,100,000,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Market Capitalization Equal to or Exceeds $8.1 billion
Business Acquisition [Line Items]
Cobalt success payment	500,000,000.0
Cobalt Biomedicine, Inc | Acquisition Agreement | IPR&D
Business Acquisition [Line Items]
Business combination, intangible assets	$ 59,200,000